• 1
    Ferlay J,Pisani P,Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. Lyon: IARC, 2004.
  • 2
    National Board of Health and Welfare.Cancer incidence in Sweden, 2006,
  • 3
    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 2004; 83: 11438.
  • 4
    Brennan P,Bogillot O,Cordier S,Greiser E,Schill W,Vineis P,Lopez-Abente G,Tzonou A,Chang-Claude J,Bolm-Audorff U,Jockel KH,Donato F, et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 2000; 86: 28994.
  • 5
    Brennan P,Bogillot O,Greiser E,Chang-Claude J,Wahrendorf J,Cordier S,Jockel KH,Lopez-Abente G,Tzonou A,Vineis P,Donato F,Hours M, et al. The contribution of cigarette smoking to bladder cancer in women (pooled European data). Cancer Causes Control 2001; 12: 4117.
  • 6
    Gandini S,Botteri E,Iodice S,Boniol M,Lowenfels AB,Maisonneuve P,Boyle P. Tobacco smoking and cancer: a meta-analysis. Int J Cancer 2008; 122: 15564.
  • 7
    IARC. Tobacco smoking: monographs on the evaluation of carcinogenic risk of chemicals to. humans, vol. 38. Lyon, France: International Agency for Research on Cancer, 1986.
  • 8
    Nordlund LA,Carstensen JM,Pershagen G. Cancer incidence in female smokers: a 26-year follow-up. Int J Cancer 1997; 73: 6258.
  • 9
    Steineck G,Norell SE,Feychting M. Diet, tobacco and urothelial cancer. A 14-year follow-up of 16,477 subjects. Acta Oncol 1988; 27: 3237.
  • 10
    Zeegers MP,Kellen E,Buntinx F,van den Brandt PA. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol 2004; 21: 392401.
  • 11
    Boffetta P,Kogevinas M. Introduction: epidemiologic research and prevention of occupational cancer in Europe. Environ Health Perspect 1999; 107 ( Suppl 2): 22931.
  • 12
    Murta-Nascimento C,Schmitz-Drager BJ,Zeegers MP,Steineck G,Kogevinas M,Real FX,Malats N. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol 2007; 25: 28595.
  • 13
    Sanderson S,Salanti G,Higgins J. Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: a literature-based systematic HuGE review and evidence synthesis. Am J Epidemiol 2007; 166: 74151.
  • 14
    Murta-Nascimento C,Silverman DT,Kogevinas M,Garcia-Closas M,Rothman N,Tardon A,Garcia-Closas R,Serra C,Carrato A,Villanueva C,Dosemeci M,Real FX, et al. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol Biomarkers Prev 2007; 16: 1595600.
  • 15
    Kellen E,Hemelt M,Broberg K,Golka K,Kristensen VN,Hung RJ,Matullo G,Mittal RD,Porru S,Povey A,Schulz WA,Shen J, et al. Pooled analysis and meta-analysis of the glutathione S-transferase P1 Ile 105Val polymorphism and bladder cancer: a HuGE-GSEC review. Am J Epidemiol 2007; 165: 122130.
  • 16
    Garcia-Closas M,Malats N,Silverman D,Dosemeci M,Kogevinas M,Hein DW,Tardon A,Serra C,Carrato A,Garcia-Closas R,Lloreta J,Castano-Vinyals G, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005; 366: 64959.
  • 17
    Andrew AS,Karagas MR,Nelson HH,Guarrera S,Polidoro S,Gamberini S,Sacerdote C,Moore JH,Kelsey KT,Demidenko E,Vineis P,Matullo G. DNA repair polymorphisms modify bladder cancer risk: a multi-factor analytic strategy. Hum Hered 2008; 65: 10518.
  • 18
    Wu X,Lin X,Dinney CP,Gu J,Grossman HB. Genetic polymorphism in bladder cancer. Front Biosci 2007; 12: 192213.
  • 19
    Plna K,Hemminki K. Familial bladder cancer in the National Swedish Family Cancer Database. J Urol 2001; 166: 212933.
  • 20
    Hemminki K,Granstrom C,Sundquist J,Lorenzo Bermejo J. The nation-wide Swedish Family-Cancer Database used to assess familial risks of prostate cancer during rapidly increasing incidence. Hered Cancer Clin Pract 2006; 4: 18692.
  • 21
    Hemminki K,Li X,Plna K,Granstrom C,Vaittinen P. The nation-wide Swedish family-cancer database—updated structure and familial rates. Acta Oncol 2001; 40: 7727.
  • 22
    Lorenzo Bermejo J,Hemminki K. Familial risk of cancer shortly after diagnosis of the first familial tumor. J Natl Cancer Inst 2005; 97: 15759.
  • 23
    Lorenzo Bermejo J,Hemminki K. Re: Risks of cancer and families. J Natl Cancer Inst 2006; 98: 5634; author reply 564.
  • 24
    Engholm GS,Storm HH,Ferlay J,Christensen N,Bray F,Olafsdottir E,Pukkala E,Talbäck M. NORDCAN: Cancer incidence and mortality in the Nordic countries, Version 3.0. Copenhagen: Association of Nordic Cancer Registries, Danish Cancer Society, 2007.
  • 25
    Grant W. Smoking, Parkinson's disease and melanoma. Cancer Epidemiol Biomarkers Prev 2007; 16: 2517.
  • 26
    Odenbro A,Gillgren P,Bellocco R,Boffetta P,Hakansson N,Adami J. The risk for cutaneous malignant melanoma, melanoma in situ and intraocular malignant melanoma in relation to tobacco use and body mass index. Br J Dermatol 2007; 156: 99105.
  • 27
    Lorenzo Bermejo J,Hemminki K. Familial lung cancer and aggregation of smoking habits: a simulation of the effect of shared environmental factors on the familial risk of cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 173840.
  • 28
    Aben KK,Witjes JA,Schoenberg MP,Hulsbergen-van de Kaa C,Verbeek AL,Kiemeney LA. Familial aggregation of urothelial cell carcinoma. Int J Cancer 2002; 98: 2748.
  • 29
    Goldgar DE,Easton DF,Cannon-Albright LA,Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86: 16008.
  • 30
    Engel LS,Taioli E,Pfeiffer R,Garcia-Closas M,Marcus PM,Lan Q,Boffetta P,Vineis P,Autrup H,Bell DA,Branch RA,Brockmoller J, et al. Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a huge review. Am J Epidemiol 2002; 156: 95109.
  • 31
    Figueroa JD,Malats N,Rothman N,Real FX,Silverman D,Kogevinas M,Chanock S,Yeager M,Welch R,Dosemeci M,Tardon A,Serra C, et al. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis 2007; 28: 178893.
  • 32
    Chao C,Zhang ZF,Berthiller J,Boffetta P,Hashibe M. NAD(P)H: quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 97987.
  • 33
    Hemminki K,Lorenzo Bermejo J. Constraints for genetic association studies imposed by attributable fraction and familial risk. Carcinogenesis 2007; 28: 64856.
  • 34
    Lorenzo Bermejo J. Gene-environment interactions and familial relative risks. Hum Hered 2008; 66: 1709.
  • 35
    Hemminki K,Sundquist J,Lorenzo Bermejo J. Familial risks for cancer as the basis for evidence-based clinical referral and counseling. Oncologist 2008; 13: 23947.
  • 36
    Burton PR,Tobin MD,Hopper JL. Key concepts in genetic epidemiology. Lancet 2005; 366: 94151.